Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 8, 2015, Pages 9351-9359

  Zhu, Hailong ^a   Qin, Huali ^b   Huang, Ziling ^a,c   Li, Shuai ^a   Zhu, Xuyou ^a   He, Jian ^a   Yang, Jing ^d   Yu, Xiaoting ^a   Yi, Xianghua ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Zhaoxiang Community Health Centre   (China)

^c Department of Pathology   (China)

^d HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Immunotherapy; PD L1; Serrated adenocarcinoma; Tumor prognosis

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADENOCARCINOMA; COLORECTAL TUMOR; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; SURVIVAL RATE;

ADENOCARCINOMA; ANTIGENS, CD274; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 85012982978     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Deschoolmeester V, Baay M, Specenier P, Lardon F and Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010; 15: 699-731.
2. Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
3. Minoo P, Zlobec I, Peterson M, Terracciano L and Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010; 37: 707-718.
4. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Ber-Tagnolli MM and Boland CR. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003; 63: 1608-1614.
5. Lao VV and Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
6. Pritchard CC and Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60: 116-129.
7. Ishida Y, Agata Y, Shibahara K and Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 1992; 11: 3887-3895.
8. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prevost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N and Zitvogel L. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71: 5393-5399.
9. Fanoni D, Tavecchio S, Recalcati S, Balice Y, Venegoni L, Fiorani R, Crosti C and Berti E. New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett 2011; 134: 157-160.
10. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB and Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009; 69: 1694-1703.
11. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE and Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
12. Dong H, Zhu G, Tamada K and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
13. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E and Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
14. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR and Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
15. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ and Carreno BM. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643.
16. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T and Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64: 1140-1145.
17. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC and Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101: 17174-17179.
18. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006; 108: 19-24.
19. Haghshenas MR, Naeimi S, Talei A, Ghaderi A and Erfani N. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep 2011; 38: 4205-4210.
20. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T and Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104: 3360-3365.
21. Loos M, Langer R, Schuster T, Gertler R, Walch A, Rauser S, Friess H and Feith M. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. Ann Thorac Surg 2011; 91: 1025-1031.
22. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, Wu X, Wang L, Wang J and Liu H. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8: e65821.
23. Li ZS and Li Q. [The latest 2010 WHO classification of tumors of digestive system]. Zhonghua Bing Li Xue Za Zhi 2011; 40: 351-354.
24. Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50: 131-150.
25. Garcia-Solano J, Perez-Guillermo M, Conesa-Zamora P, Acosta-Ortega J, Trujillo-Santos J, Cerezuela-Fuentes P and Makinen MJ. Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol 2010; 41: 1359-1368.
26. Erkan M, KleeffJ, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA and Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 24: 4421-4432.
27. Jass JR and Smith M. Sialic acid and epithelial differentiation in colorectal polyps and cancer a morphological, mucin and lectin histochemical study. Pathology 1992; 24: 233-242.
28. Makinen MJ, George SM, Jernvall P, Makela J, Vihko P and Karttunen TJ. Colorectal carcino ma associated with serrated adenoma prevalence, histological features, and prognosis. J Pathol 2001; 193: 286-294.
29. Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, Schwartz S Jr, Arango D, Makinen MJ and Aaltonen LA. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007; 26: 312-320.
30. Oh K, Redston M and Odze RD. Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. Hum Pathol 2005; 36: 101-111.
31. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M and Farraye FA. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006; 30: 1491-1501.
32. Tuppurainen K, Makinen JM, Junttila O, Liakka A, Kyllonen AP, Tuominen H, Karttunen TJ and Makinen MJ. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol 2005; 207: 285-294.
33. O'Brien MJ, Yang S, Huang CS, Shepherd C, Cerda S and Farraye FA. The serrated polyp pathway to colorectal carcinoma. Diagnostic Histopathology 2008; 14: 78-93.
34. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M and Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157.
35. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH and Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895.
36. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N and Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322.
37. Nishimura H, Nose M, Hiai H, Minato N and Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
38. Okazaki T and Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-824.
39. Keir ME, Butte MJ, Freeman GJ and Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
40. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304.
41. Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Cluff-Jones K, Magee JM, Panchakshari RA, Rodig SJ, Kepler TB and Alt FW. Microbial colonization influences early B-lineage development in the gut lamina propria. Nature 2013; 501: 112-115.
42. Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, O'Leary CE, Oliver PM, Kolls JK, Weiser JN and Worthen GS. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 2014; 20: 524-530.
43. Schwiertz A, Gruhl B, Lobnitz M, Michel P, Radke M and Blaut M. Development of the intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term infants. Pediatr Res 2003; 54: 393-399.
44. Pflughoeft KJ and Versalovic J. Human microbiome in health and disease. Annu Rev Pathol 2012; 7: 99-122.
45. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC and Tornillo L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242